Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;237(7):2796-2807.
doi: 10.1002/jcp.30760. Epub 2022 Apr 29.

Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases

Feng Zeng  1   2   3 , Jiani Zhang  4 , Xi Jin  1   2   3 , Qianjin Liao  3 , Zhifang Chen  5 , Gengqiu Luo  6 , Yanhong Zhou  1   2   3
Affiliations
Review

Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases

Feng Zeng et al. J Cell Physiol. 2022 Jul.

Abstract

CD38 is a multifunctional receptor and enzyme present on the surface of B lymphocytes, which can induce B lymphocytes proliferation and apoptosis by crosslinking related cytokines to affect the function of B cells, thus affecting immune regulation in humans and promoting tumorigenesis. The level of CD38 expression in B cells has become an important factor in the clinical diagnosis, treatment, and prognosis of malignant tumors and other related diseases. Therefore, studying the relationship between CD38 expression on the surface of B cells and the occurrence of the disease is of great significance for elucidating its association with disease pathogenesis and the clinical targeted therapy. In this paper, we review the effects of CD38 on B-cell activation, proliferation, and differentiation, and elaborate the functional role and mechanism of CD38 expression on B cells. We also summarize the relationship between the level of CD38 expression on the surface of B cells and the diagnosis, treatment, and prognosis of various diseases, as well as the potential use of targeted CD38 treatment for related diseases. This will provide an important theoretical basis for the scientific research and clinical diagnosis and treatment of B-cell-related diseases.

Keywords: B lymphocytes; B-cell chronic lymphocytic leukemia; CD38; Molecular targets; Multiple myeloma.

PubMed Disclaimer

References

REFERENCES

    1. Blair, H. A. (2017). Daratumumab: A review in relapsed and/or refractory multiple myeloma. Drugs, 77(18), 2013-2024. https://doi.org/10.1007/s40265-017-0837-7
    1. Buffa, S., Pellicanò, M., Bulati, M., Martorana, A., Goldeck, D., Caruso, C., & Colonna-Romano, G. (2013). A novel B cell population revealed by a CD38/CD24 gating strategy: CD38(−)CD24 (−) B cells in centenarian offspring and elderly people. Age, 35(5), 2009-2024. https://doi.org/10.1007/s11357-012-9488-5
    1. Cencioni, M. T., Ali, R., Nicholas, R., & Muraro, P. A. (2021). Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS. Multiple Sclerosis, 27(8), 1187-1197. https://doi.org/10.1177/1352458520951536
    1. Chang, C. C., Liu, C. Z., & Cleveland, R. P. (2003). Relative importance of CD38 expression over myeloid-associated markers expression in predicting the clinical course of B-CLL patients. Leukemia & Lymphoma, 44(6), 977-982. https://doi.org/10.1080/1042819031000076990
    1. Chen, M., Zhang, L., Ren, Y., Zhang, K., Yang, Y., Fang, Y., Yan, X., Peng, D., Gao, C., & Li, S. (2016). Defective function of CD24(+)CD38(+) regulatory B cells in ankylosing spondylitis. DNA and Cell Biology, 35(2), 88-95. https://doi.org/10.1089/dna.2015.3046

Publication types

MeSH terms

LinkOut - more resources